Telocyte-derived pentraxin 3 enables vascular pruning as a key driver in infantile hemangioma regression
Abstract
The natural course of infantile hemangioma (IH), a benign vascular infantile tumor, is marked by the initial rapid proliferation of dystrophic capillaries, followed by a regression phase, which is either spontaneous or induced by the first line treatment propranolol. Although endothelial cells have been at the center of most studies, the role of stromal cells in this vascular remodeling has remained unclear. Telocytes, which are stromal cells that may be targeted by propranolol, are involved in tissue organization and angiogenesis, suggesting their role in vascular remodeling during the regression of IH. To assess changes in vascular architecture of IH and the role of telocytes, we used Skin-iDISCO + 3-Dimensions (3D) sample imaging and in vitro models with patient-derived telocytes. Perivascular telocytes exhibited increased dendricity during regression, indicating their activation. Telocytes secretome profiling revealed a complex inhibitory program, with pentraxin 3 (PTX3) emerging as a central effector. 3D multicellular disease models demonstrated a paracrine effect blocking endothelial fibroblast growth factor receptors (FGFR) signaling via FGF2–PTX3 interaction, thereby strongly regulating endothelial proliferation, sprouting, and activation. In vitro mechanistic study and collagen IV staining analysis revealed that vascular regression is at least partially due to vascular pruning. These findings highlight the pivotal role of telocytes in orchestrating vascular remodeling during IH regression, opening therapeutic perspectives for inducing vascular normalization in pathological angiogenesis, including cancer.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (13)
Léa Pechtimaldjian
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
Marie-Laure Jullié
Service de Pathologie, Centre Hospitalier Universitaire de Bordeaux
Chloé Rousson
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
Faiza Laanani
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
Julie Clachet
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
Yamina Idrissi
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
Maya Loot
Service de Chirurgie Pédiatrique, Centre Hospitalier Universitaire de Bordeaux
Muriel Cario-Andre
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
Sorilla Prey
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
Alain Taieb
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
Christine Leauté-Labrèze
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
Thomas Mathivet
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312
François Moisan
University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312